A review of bispecific antibodies and antibody constructs in oncology and clinical challenges-Reference-Cited by-同舟云学术

A review of bispecific antibodies and antibody constructs in oncology and clinical challenges

Published:2019-09 Issue: Volume:201 Page:103-119
ISSN:0163-7258
Container-title:Pharmacology & Therapeutics
language:en
Short-container-title:Pharmacology & Therapeutics

Author:

Suurs Frans V.,Lub-de Hooge Marjolijn N.,de Vries Elisabeth G.E.,de Groot Derk Jan A.

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference172 articles.

1. First-in-human phase 1/2 study of MCLA-128, a full length IgG1 bispecific antibody targeting HER2 and HER3: Final phase 1 data and preliminary activity in HER2+ metastatic breast cancer (MBC);Alsina;Journal of Clinical Oncology,2017

2. Pretargeted imaging and therapy;Altai;Journal of Nuclear Medicine,2017

3. Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans;Amann;Cancer Immunology, Immunotherapy,2009

4. Novel carcinoembryonic antigen T-cell bispecific (CEA-TCB) antibody: Preliminary clinical data as a single agent and in combination with atezolizumab in patients with metastatic colorectal cancer (mCRC);Argilés;Annals of Oncology,2017

5. Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: Description of a novel modular targeting system;Arndt;Leukemia,2014

Cited by 210 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potent antitumor activity of a bispecific T-cell engager antibody targeting the intracellular antigen KRAS G12V;Biomolecules and Biomedicine;2024-09-06

2. Vaccine enhancement and improved immunogenicity using erythrocytes as carriers;Medical Hypotheses;2024-09

3. A novel bispecific peptide targeting PD-1 and PD-L1 with combined antitumor activity of T-cells derived from the patients with TSCC;International Immunopharmacology;2024-09

4. Investigation on environmental factors contributing to bispecific antibody stability and the reversal of self-associated aggregates;Bioresources and Bioprocessing;2024-08-23

5. Clinical Progresses and Challenges of Bispecific Antibodies for the Treatment of Solid Tumors;Molecular Diagnosis & Therapy;2024-08-22